Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Refractory/Active SLE
NCT06789107Phase 1Recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab in systemic lupus erythematosus (SLE). Primary endpoint: Safety of Blinatumomab at 12 weeks. Started Dec 2024; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06789107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789107.